missouri medicaid glp-1 to stop covering weight-loss drugs for obesity in New Hampshire • New Hampshire Bulletin Pennsylvania Medicaid stopped covering GLP-1s

Brain Pathol 13(4):440451 Albasanz JL et al (2008) Up-regulation of adenosine receptors in the frontal cortex in Alzheimers disease

From an integrative perspective, we always work to put lab data in the context of your health history, symptoms, and goals

Kwon, D

For example, a 2000 mAh battery with a 20C rating is: 2 Ah * 20C = 40 amps

Phase 2 obesity trial (NEJM 2023) adverse events by maintenance dose (where a dose had two escalation arms, the range across both arms is shown): Phase 2 type 2 diabetes trial (Lancet 2023): mild-to-moderate gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were reported in 35% of retatrutide participants ranging from 13% at 0.5 mg to 50% in the 8 mg fast-escalation group compared with 13% on placebo and 35% on dulaglutide 1.5 mg